- Home
- KROS vs IGD Comparison
KROS vs IGD Comparison
Compare KROS & IGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- IGD
- Stock Information
- Founded
- KROS 2015
- IGD N/A
- Country
- KROS United States
- IGD United States
- Employees
- KROS N/A
- IGD N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- IGD Trusts Except Educational Religious and Charitable
- Sector
- KROS Health Care
- IGD Finance
- Exchange
- KROS Nasdaq
- IGD Nasdaq
- Market Cap
- KROS 460.6M
- IGD 432.2M
- IPO Year
- KROS 2020
- IGD N/A
- Fundamental
- Price
- KROS $11.00
- IGD $5.43
- Analyst Decision
- KROS Buy
- IGD
- Analyst Count
- KROS 11
- IGD 0
- Target Price
- KROS $45.33
- IGD N/A
- AVG Volume (30 Days)
- KROS 2.1M
- IGD 215.3K
- Earning Date
- KROS 02-26-2025
- IGD 01-01-0001
- Dividend Yield
- KROS N/A
- IGD 9.15%
- EPS Growth
- KROS N/A
- IGD N/A
- EPS
- KROS N/A
- IGD N/A
- Revenue
- KROS $651,000.00
- IGD N/A
- Revenue This Year
- KROS $303.27
- IGD N/A
- Revenue Next Year
- KROS N/A
- IGD N/A
- P/E Ratio
- KROS N/A
- IGD N/A
- Revenue Growth
- KROS 8037.50
- IGD N/A
- 52 Week Low
- KROS $9.78
- IGD $4.60
- 52 Week High
- KROS $73.00
- IGD $5.26
- Technical
- Relative Strength Index (RSI)
- KROS 24.79
- IGD 45.33
- Support Level
- KROS $11.04
- IGD $5.45
- Resistance Level
- KROS $11.99
- IGD $5.51
- Average True Range (ATR)
- KROS 0.60
- IGD 0.06
- MACD
- KROS 1.20
- IGD 0.00
- Stochastic Oscillator
- KROS 43.99
- IGD 45.45
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About IGD Voya Global Equity Dividend and Premium Opportunity Fund
Voya Global Equity Dividend and Premium Opportunity Fund are a United States-based diversified, closed-end Fund. The primary objective of the Fund is to seek to provide investors with a high level of income from a portfolio of common stocks with historically attractive dividend yields and premiums from call option writing. The secondary investment objective of the company is capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in a portfolio of common stocks of dividend-paying companies located throughout the world.